Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
Conference call and webcast to begin at 8:30 AM ET
電話會議和網絡直播將於東部時間上午8:30開始
AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.
德克薩斯州奧斯汀，2024年10月31日(全球新聞社)——cassava sciences公司(納斯達克: SAVA)，一家專注於阿爾茨海默病的臨床階段生物技術公司，今天宣佈將於11月7日星期四上午8:30舉行電話會議。
| Event details: | |
| Date: | Thursday, November 7th |
| Time: | 8:30 a.m. Eastern Time |
| Audio Webcast: | |
| Or | |
| Audio Webcast: | |
| 事件詳情： | |
| 日期： | 11月7日星期四 |
| 時間： | 美國東部時間上午8:30 |
| 音頻網絡廣播： | |
| 或者 | |
| 音頻網絡廣播： | |
A replay of the audio webcast will also be available on the "Company Presentations" page of the Cassava Sciences website for 90 days following the webcast.
音頻網絡廣播的重播也將在cassava sciences網站的"公司演示"頁面上提供，持續90天。
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer's disease.
關於Cassava Sciences，Inc.
cassava sciences是一家總部位於得克薩斯州奧斯汀的處於臨床階段的生物技術公司。我們的使命是檢測和治療神經退行性疾病，比如阿爾茨海默氏病。
Simufilam is Cassava Sciences' small molecule oral drug candidate currently in Phase 3 clinical trials for the treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain. Cassava Sciences believes that simufilam interrupts amyloid-β42 binding to receptors in the brain and may affect the Alzheimer's disease process. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.
Simufilam是cassava sciences的口服小分子藥物候選，目前正在進行用於治療阿爾茨海默氏病的三期臨床試驗。Simufilam瞄準filamin A上的特定位點，這是大腦中某些受體相互作用至關重要的支架蛋白。cassava sciences相信，simufilam打斷了β澱粉樣蛋白42與腦部受體的結合，並可能影響阿爾茨海默氏病的發展過程。cassava sciences擁有其產品候選和相關技術的獨家全球使用權，無需向任何第三方支付版稅。
For more information, please visit:
欲了解更多信息，請訪問：
For More Information Contact:
欲知詳情，請聯繫：
Investors
Sandya van der Weid
svonderweid@lifesciadvisors.com
投資者
Sandya van der Weid
svonderweid@lifesciadvisors.com
Media
Sitrick And Company
Mike_Sitrick@Sitrick.com
媒體
Sitrick And Company
Mike_Sitrick@Sitrick.com
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@CassavaSciences.com
公司
Eric Schoen, 首席財務官
(512) 501-2450
ESchoen@CassavaSciences.com
譯文內容由第三人軟體翻譯。
